FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387398407> ?p ?o ?g. }

• W4387398407 abstract "The field of cancer immunotherapy has shown significant growth, and researchers are now focusing on effective strategies to enhance and prolong local immunomodulation. Injectable hydrogels IHs have emerged as versatile platforms for encapsulating and controlling the release of small molecules and cells, drawing significant attention for their potential to enhance antitumor immune responses while inhibiting metastasis and recurrence. IHs delivering natural killer (NK) cells, T cells, and antigen-presenting cells (APCs) offer a viable method for treating cancer. Indeed, it can bypass the extracellular matrix and gradually release small molecules or cells into the tumor microenvironment, thereby boosting immune responses against cancer cells. This review provides an overview of the recent advancements in cancer immunotherapy using IHs for delivering NK cells, T cells, APCs, chemoimmunotherapy, radio-immunotherapy, and photothermal-immunotherapy. First, we introduce IHs as a delivery matrix, then summarize their applications for the local delivery of small molecules and immune cells to elicit robust anticancer immune responses. Additionally, we discuss recent progress in IHs systems used for local combination therapy, including chemoimmunotherapy, radio-immunotherapy, photothermal-immunotherapy, photodynamic-immunotherapy, and gene-immunotherapy. By comprehensively examining the utilization of IHs in cancer immunotherapy, this review aims to highlight the potential of IHs as effective carriers for immunotherapy delivery, facilitating the development of innovative strategies for cancer treatment. In addition, we demonstrate that using hydrogel-based platforms for the targeted delivery of immune cells, such as NK cells, T cells, and DCs, has remarkable potential in cancer therapy. These innovative approaches have yielded substantial reductions in tumor growth, showcasing the ability of hydrogels to enhance the efficacy of immune-based treatments. STATEMENT OF SIGNIFICANCE: As cancer immunotherapy continues to expand, the mode of therapeutic agent delivery becomes increasingly critical. This review spotlights the forward-looking progress of Injectable Hydrogels (IHs), emphasizing their potential to revolutionize localized immunotherapy delivery. By efficiently encapsulating and controlling the release of essential immune components such as T cells, NK cells, APCs, and various therapeutic agents, IHs offer a pioneering pathway to amplify immune reactions, moderate metastasis, and reduce recurrence. Their adaptability further shines when considering their role in emerging combination therapies, including chemoimmunotherapy, radio-immunotherapy, and photothermal-immunotherapy. Understanding IHs' significance in cancer therapy is essential, suggesting a shift in cancer treatment dynamics and heralding a novel period of focused, enduring, and powerful therapeutic strategies." @default.
• W4387398407 created "2023-10-07" @default.
• W4387398407 creator A5006763901 @default.
• W4387398407 creator A5007244623 @default.
• W4387398407 creator A5019473576 @default.
• W4387398407 creator A5023198820 @default.
• W4387398407 creator A5027716648 @default.
• W4387398407 creator A5033056518 @default.
• W4387398407 creator A5039506035 @default.
• W4387398407 creator A5044400718 @default.
• W4387398407 creator A5046486757 @default.
• W4387398407 creator A5051429881 @default.
• W4387398407 creator A5058573930 @default.
• W4387398407 creator A5058887704 @default.
• W4387398407 creator A5059311024 @default.
• W4387398407 creator A5071338912 @default.
• W4387398407 creator A5084438266 @default.
• W4387398407 creator A5084450352 @default.
• W4387398407 creator A5093015789 @default.
• W4387398407 creator A5093015790 @default.
• W4387398407 creator A5093015791 @default.
• W4387398407 creator A5093015792 @default.
• W4387398407 creator A5093015793 @default.
• W4387398407 date "2023-10-01" @default.
• W4387398407 modified "2023-10-14" @default.
• W4387398407 title "Injectable Hydrogels for Personalized Cancer Immunotherapies" @default.
• W4387398407 cites W1755626805 @default.
• W4387398407 cites W1970274313 @default.
• W4387398407 cites W1976928264 @default.
• W4387398407 cites W1997209259 @default.
• W4387398407 cites W1997353385 @default.
• W4387398407 cites W2015821654 @default.
• W4387398407 cites W2033441782 @default.
• W4387398407 cites W2041139178 @default.
• W4387398407 cites W2060239018 @default.
• W4387398407 cites W2060870743 @default.
• W4387398407 cites W2062608800 @default.
• W4387398407 cites W2082109539 @default.
• W4387398407 cites W2083793926 @default.
• W4387398407 cites W2090459898 @default.
• W4387398407 cites W2118087101 @default.
• W4387398407 cites W2120426523 @default.
• W4387398407 cites W2122743263 @default.
• W4387398407 cites W2143523733 @default.
• W4387398407 cites W2165372444 @default.
• W4387398407 cites W2173331143 @default.
• W4387398407 cites W2302435047 @default.
• W4387398407 cites W2345520280 @default.
• W4387398407 cites W2486039867 @default.
• W4387398407 cites W2521381098 @default.
• W4387398407 cites W2564584078 @default.
• W4387398407 cites W2586195606 @default.
• W4387398407 cites W2596533219 @default.
• W4387398407 cites W2606353657 @default.
• W4387398407 cites W2613949801 @default.
• W4387398407 cites W2620567182 @default.
• W4387398407 cites W2750783216 @default.
• W4387398407 cites W2752663582 @default.
• W4387398407 cites W2758072820 @default.
• W4387398407 cites W2769017630 @default.
• W4387398407 cites W2788206402 @default.
• W4387398407 cites W2789332370 @default.
• W4387398407 cites W2791931250 @default.
• W4387398407 cites W2792358501 @default.
• W4387398407 cites W2795915709 @default.
• W4387398407 cites W2796829698 @default.
• W4387398407 cites W2797530783 @default.
• W4387398407 cites W2801055843 @default.
• W4387398407 cites W2801138628 @default.
• W4387398407 cites W2803332784 @default.
• W4387398407 cites W2807515528 @default.
• W4387398407 cites W2808870773 @default.
• W4387398407 cites W2864786814 @default.
• W4387398407 cites W2884102832 @default.
• W4387398407 cites W2894477662 @default.
• W4387398407 cites W2899290758 @default.
• W4387398407 cites W2899851841 @default.
• W4387398407 cites W2902882570 @default.
• W4387398407 cites W2903348871 @default.
• W4387398407 cites W2904297611 @default.
• W4387398407 cites W2905964845 @default.
• W4387398407 cites W2906972414 @default.
• W4387398407 cites W2909301717 @default.
• W4387398407 cites W2912711791 @default.
• W4387398407 cites W2914301545 @default.
• W4387398407 cites W2925023764 @default.
• W4387398407 cites W2937022717 @default.
• W4387398407 cites W2941481939 @default.
• W4387398407 cites W2942172826 @default.
• W4387398407 cites W2942224185 @default.
• W4387398407 cites W2945785095 @default.
• W4387398407 cites W2950627686 @default.
• W4387398407 cites W2957011758 @default.
• W4387398407 cites W2971503724 @default.
• W4387398407 cites W2972159813 @default.
• W4387398407 cites W2975798969 @default.
• W4387398407 cites W2979845453 @default.
• W4387398407 cites W2989435057 @default.
• W4387398407 cites W2989957419 @default.
• W4387398407 cites W2991928778 @default.

• next